Request Trial
shutterstock_1395147236_poptika
Poptika / Shutterstock.com
15 December 2020PharmaSally Shorthose and Rumana Khanom

What 2020 means for the life sciences

2020 has been a tumultuous year in many respects and the conflation of a pandemic and the impact of the UK’s departure from the EU has profound implications for the life sciences and medical devices industries in the UK and the EU. In this article, we consider how and why these events will have such an effect and how affected businesses may need to prepare for these.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Pharma
Dr Reddy’s eyes appeal stakes as Boehringer hearing ends
22 October 2026   Questions over what Boehringer’s patents actually proved dominated the final day of the hearing, but a push for a further finding raised the stakes, with a possible appeal threatening to keep Dr Reddy’s off the market even if it won.
Pharma
Amarin and Hikma call time on six-year skinny label fight
22 October 2026   Following a major US Supreme Court win for generics, the landmark dispute has finally come to an end. A new filing brings closure to a case that raised questions over skinny labelling and induced patent infringement.
Pharma
Boehringer accuses Dr Reddy’s of ‘weaponising’ plausibility
20 October 2026   In closing arguments last week, the drugmaker urged the UK Patents Court to reject an overly critical approach to plausibility and consider what its patents disclose when read as a whole rather than individually.


Editor's picks

In-house counsel rethink patent filing strategies as costs mount
In-house counsel
In-house counsel rethink patent filing strategies as costs mount
3 November 2026

Editor's picks

In-house counsel
In-house counsel rethink patent filing strategies as costs mount
3 November 2026

More features

Regulatory and patent teams must align, say Amgen, Genentech, ORIC
LSPN Fall: AI agents are taking on patent work. What’s left for lawyers?
In-house counsel rethink patent filing strategies as costs mount
UK unveils £1bn sector investment push after recent setbacks
Justice Joanna Smith appointed to interim High Court role as Sir Colin Birss replaces Sir Geoffrey Vos
Oura targets Ultrahuman’s redesigned smart ring following import ban
Meril turns the tables on Edwards with European patent revocation
Latham lands pharma and tech expert in London